Quick Answer
Atara Biotherapeutics, Inc. reported R&D Expense of $37.45 million for fiscal year 2025.
Atara Biotherapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $37.45M | -75.3% |
| 2024 | $151.48M | -32.6% |
| 2023 | $224.78M | -17.5% |
| 2022 | $272.53M | -3.4% |
| 2021 | $282.00M | +15.3% |
| 2020 | $244.65M | +13.2% |
| 2019 | $216.10M | +29.0% |
| 2018 | $167.46M | +106.2% |
| 2017 | $81.21M | +43.7% |
| 2016 | $56.51M | +35.8% |
| 2015 | $41.62M | +169.4% |
| 2014 | $15.45M | +672.3% |
| 2014 | $2.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.92M | -93.3% | -60.0% |
| June 30, 2025 | $7.31M | -78.1% | -73.4% |
| March 31, 2025 | $27.43M | -39.7% | -37.5% |
| September 30, 2024 | $43.92M | -22.8% | +31.8% |
| June 30, 2024 | $33.33M | -40.6% | -26.8% |
| March 31, 2024 | $45.51M | -26.8% | -20.0% |
| September 30, 2023 | $56.89M | -18.9% | +1.3% |
| June 30, 2023 | $56.14M | -13.5% | -9.7% |
- Atara Biotherapeutics, Inc. showed a decrease of -75.3% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Atara Biotherapeutics, Inc.’s r&d expense has grown by 1772.2% (from $2.00 million to $37.45 million).
- The most recent figure is from Atara Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: